Skip to content
10-Q

Quarterly Report

Elicio Therapeutics, Inc. ELTX

0001601485-26-000042

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 19.09M sh
Shares Diluted Q1 2026 · Mar 31, 2026 18.21M sh
Shares Diluted Q1 2026 · Mar 31, 2025 12.95M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$11.65M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$10.12M
Long Term Debt Q1 2026 · Mar 31, 2026 $9.48M
Long Term Debt Q1 2026 · Dec 31, 2025 $9.41M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.95M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $18.56M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $18.35M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$1.44M
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.64M
Stockholders Equity Q1 2026 · Mar 31, 2025 $8.9M
Stockholders Equity Q1 2026 · Dec 31, 2024 −$11.31M
Current Liabilities Q1 2026 · Mar 31, 2026 $7.23M
Current Liabilities Q1 2026 · Dec 31, 2025 $8.11M
Total Liabilities Q1 2026 · Mar 31, 2026 $24.13M
Total Liabilities Q1 2026 · Dec 31, 2025 $24.23M
Current Assets Q1 2026 · Mar 31, 2026 $16.2M
Current Assets Q1 2026 · Dec 31, 2025 $19.31M
Total Assets Q1 2026 · Mar 31, 2026 $22.69M
Total Assets Q1 2026 · Dec 31, 2025 $25.86M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.65
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.87
Eps Basic Q1 2026 · Mar 31, 2026 −$0.65
Eps Basic Q1 2026 · Mar 31, 2025 −$0.87
Sga Expense Q1 2026 · Mar 31, 2026 $3.85M
Sga Expense Q1 2026 · Mar 31, 2025 $2.96M
Rd Expense Q1 2026 · Mar 31, 2026 $6.76M
Rd Expense Q1 2026 · Mar 31, 2025 $7.78M
Net Income Q1 2026 · Mar 31, 2026 −$11.82M
Net Income Q1 2026 · Mar 31, 2025 −$11.21M
Operating Income Q1 2026 · Mar 31, 2026 −$10.6M
Operating Income Q1 2026 · Mar 31, 2025 −$10.74M